PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
Eli Lilly Japan notched up a revenue rise of 7.0% to log 260.1 billion yen in 2017, buoyed by its major antidepressant/painkiller Cymbalta (duloxetine) and cancer drug Cyramza (ramucirumab), the company said on March 22. The company moved up the…
To read the full story
Related Article
- Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
- Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
March 30, 2018
- Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief
March 16, 2017
- Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017
BUSINESS
- Novo Nordisk Hints at GLP-1 Supply Restrictions to Curb Inappropriate Use
October 29, 2026
- Tatsumi Finds Nitrosamine in Migraine Drug; No Recall Planned
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
- Investment Firm Kopernik Lifts Kyorin Voting Stake Above 10%
October 29, 2026
- Leqembi Global Sales Climb to 61.5 Billion Yen in April-September: Eisai
October 29, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…